The findings suggest that enfortumab vedotin, especially combined with pembrolizumab, offers promising beneficial outcomes in metastatic urothelial carcinoma treatment,” researchers wrote.

Updated data "reinforce enfortumab vedotin and pembrolizumab as the new standard of care in frontline urothelial cancer,” said Thomas Powles, MD, MBBS.

The clinical efficacy of enfortumab vedotin plus pembrolizumab in real-world patients is compatible with that of the phase 3 EV-302 clinical trial. Treatment with enfortumab vedotin plus ...

Enfortumab vedotin and pembrolizumab combination offers transformative benefits, doubling median progression-free and overall survival in advanced urothelial carcinoma. The EV-302 trial showed a ...

Enfortumab vedotin with or without pembrolizumab offers disease control benefits for patients with upper tract urothelial cancer, said Evangelia Vlachou, MD, of Johns Hopkins Medicine. While ...

Among patients with upper tract urothelial carcinoma (UTUC) lesions, the combination of Padcev (enfortumab vedotin) and Keytruda (pembrolizumab) resulted in promising clinical activity, study results ...

Among patients with cCR, grade ≥3 treatment-related adverse events occurred in 61.7% of patients in the enfortumab vedotin plus pembrolizumab arm, compared to 71.9% in the chemotherapy arm.

Results showed enfortumab vedotin plus pembrolizumab reduced the risk of death by 49% versus chemotherapy. The median OS was 33.8 months for the combination versus 15.9 months for chemotherapy.

Results also show that reducing the Padcev dose at treatment initiation may benefit older patients with urothelial carcinoma, a type of bladder cancer.

Results showed enfortumab vedotin plus pembrolizumab reduced the risk of death by 49% versus chemotherapy = 0.51, 95% confidence interval. The median OS was 33.8 months for the combination ...

Enfortumab vedotin plus pembrolizumab cut the risk of death by 49% vs. chemo, with a median OS of 33.8 months vs. 15.9 months. The combination therapy reduced disease progression or death risk by ...